Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale

Thomas P. Giordano, David Guzman, Richard Clark, Edwin D. Charlebois, David Bangsberg

Research output: Contribution to journalArticle

230 Citations (Scopus)

Abstract

Purpose: To examine the performance of an instrument to assess adherence based on a visual analogue scale, compared to an instrument based on 3-day recall, using unannounced pill counts in the place of residence as the gold standard. Method: We prospectively assessed adherence to antiretroviral therapy in 84 marginally housed indigent HIV-infected patients who were receiving stable antiretroviral therapy in San Francisco, California, with three adherence assessments over no more than 4 months. Results: Mean adherence using the visual analogue scale, 3-day recall, and unannounced pill count methods were 82.5%, 84.2%, and 75.9%, respectively. The correlation between visual analogue scale and unannounced pill count was high (r = 0.76) and was not statistically different from that between 3-day recall and unannounced pill count (r = 0.71; p = .52). Both methods were also similarly inversely correlated with HIV viral load (r = -0.49 and -0.34, respectively; p = .22 for the difference in the correlations). The visual analogue scale correlation with unannounced pill count was stable over time and remained high in all subpopulations examined. Conclusion: A visual analogue scale to assess adherence was performed as well as a more complicated 3-day recall instrument in this diverse population. Given its simplicity, the visual analogue scale adherence instrument will be useful in research and may be useful in routine patient care.

Original languageEnglish (US)
Pages (from-to)74-79
Number of pages6
JournalHIV Clinical Trials
Volume5
Issue number2
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Visual Analog Scale
Population
Therapeutics
HIV
San Francisco
Poverty
Viral Load
Patient Care
Research

Keywords

  • Adherence
  • Antiretroviral therapy
  • Visual analogue scale

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. / Giordano, Thomas P.; Guzman, David; Clark, Richard; Charlebois, Edwin D.; Bangsberg, David.

In: HIV Clinical Trials, Vol. 5, No. 2, 03.2004, p. 74-79.

Research output: Contribution to journalArticle

Giordano, Thomas P. ; Guzman, David ; Clark, Richard ; Charlebois, Edwin D. ; Bangsberg, David. / Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. In: HIV Clinical Trials. 2004 ; Vol. 5, No. 2. pp. 74-79.
@article{56bad7cb759e420b884ef76886f1afe9,
title = "Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale",
abstract = "Purpose: To examine the performance of an instrument to assess adherence based on a visual analogue scale, compared to an instrument based on 3-day recall, using unannounced pill counts in the place of residence as the gold standard. Method: We prospectively assessed adherence to antiretroviral therapy in 84 marginally housed indigent HIV-infected patients who were receiving stable antiretroviral therapy in San Francisco, California, with three adherence assessments over no more than 4 months. Results: Mean adherence using the visual analogue scale, 3-day recall, and unannounced pill count methods were 82.5{\%}, 84.2{\%}, and 75.9{\%}, respectively. The correlation between visual analogue scale and unannounced pill count was high (r = 0.76) and was not statistically different from that between 3-day recall and unannounced pill count (r = 0.71; p = .52). Both methods were also similarly inversely correlated with HIV viral load (r = -0.49 and -0.34, respectively; p = .22 for the difference in the correlations). The visual analogue scale correlation with unannounced pill count was stable over time and remained high in all subpopulations examined. Conclusion: A visual analogue scale to assess adherence was performed as well as a more complicated 3-day recall instrument in this diverse population. Given its simplicity, the visual analogue scale adherence instrument will be useful in research and may be useful in routine patient care.",
keywords = "Adherence, Antiretroviral therapy, Visual analogue scale",
author = "Giordano, {Thomas P.} and David Guzman and Richard Clark and Charlebois, {Edwin D.} and David Bangsberg",
year = "2004",
month = "3",
doi = "10.1310/JFXH-G3X2-EYM6-D6UG",
language = "English (US)",
volume = "5",
pages = "74--79",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Thomas Land Publishers Inc.",
number = "2",

}

TY - JOUR

T1 - Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale

AU - Giordano, Thomas P.

AU - Guzman, David

AU - Clark, Richard

AU - Charlebois, Edwin D.

AU - Bangsberg, David

PY - 2004/3

Y1 - 2004/3

N2 - Purpose: To examine the performance of an instrument to assess adherence based on a visual analogue scale, compared to an instrument based on 3-day recall, using unannounced pill counts in the place of residence as the gold standard. Method: We prospectively assessed adherence to antiretroviral therapy in 84 marginally housed indigent HIV-infected patients who were receiving stable antiretroviral therapy in San Francisco, California, with three adherence assessments over no more than 4 months. Results: Mean adherence using the visual analogue scale, 3-day recall, and unannounced pill count methods were 82.5%, 84.2%, and 75.9%, respectively. The correlation between visual analogue scale and unannounced pill count was high (r = 0.76) and was not statistically different from that between 3-day recall and unannounced pill count (r = 0.71; p = .52). Both methods were also similarly inversely correlated with HIV viral load (r = -0.49 and -0.34, respectively; p = .22 for the difference in the correlations). The visual analogue scale correlation with unannounced pill count was stable over time and remained high in all subpopulations examined. Conclusion: A visual analogue scale to assess adherence was performed as well as a more complicated 3-day recall instrument in this diverse population. Given its simplicity, the visual analogue scale adherence instrument will be useful in research and may be useful in routine patient care.

AB - Purpose: To examine the performance of an instrument to assess adherence based on a visual analogue scale, compared to an instrument based on 3-day recall, using unannounced pill counts in the place of residence as the gold standard. Method: We prospectively assessed adherence to antiretroviral therapy in 84 marginally housed indigent HIV-infected patients who were receiving stable antiretroviral therapy in San Francisco, California, with three adherence assessments over no more than 4 months. Results: Mean adherence using the visual analogue scale, 3-day recall, and unannounced pill count methods were 82.5%, 84.2%, and 75.9%, respectively. The correlation between visual analogue scale and unannounced pill count was high (r = 0.76) and was not statistically different from that between 3-day recall and unannounced pill count (r = 0.71; p = .52). Both methods were also similarly inversely correlated with HIV viral load (r = -0.49 and -0.34, respectively; p = .22 for the difference in the correlations). The visual analogue scale correlation with unannounced pill count was stable over time and remained high in all subpopulations examined. Conclusion: A visual analogue scale to assess adherence was performed as well as a more complicated 3-day recall instrument in this diverse population. Given its simplicity, the visual analogue scale adherence instrument will be useful in research and may be useful in routine patient care.

KW - Adherence

KW - Antiretroviral therapy

KW - Visual analogue scale

UR - http://www.scopus.com/inward/record.url?scp=2542565696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542565696&partnerID=8YFLogxK

U2 - 10.1310/JFXH-G3X2-EYM6-D6UG

DO - 10.1310/JFXH-G3X2-EYM6-D6UG

M3 - Article

C2 - 15116282

AN - SCOPUS:2542565696

VL - 5

SP - 74

EP - 79

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 2

ER -